ARTICLE | Management Tracks
Aurion names Arnaud Lacoste CEO
Plus: David de Vries named CEO of Tr1x, and updates from Crispr, Pacbio, Alvotech and Tscan
March 29, 2025 12:13 AM UTC
Aurion Biotech Inc. has named CSO Arnaud Lacoste CEO, replacing Greg Kunst. The appointment coincides with Alcon Inc. (SIX:ALC; NYSE:ALC) taking a majority stake in Aurion. Aurion markets allogeneic cell therapy Vyznova in Japan to treat corneal endothelial disease; it’s developing a different formulation of the therapy in a Phase I/II trial, and aiming to start Phase III testing next half.
Treg and CAR Treg therapies company Tr1x Inc. named David de Vries to succeed Bill Lis as CEO effective June1. de Vries, co-founder and COO of Tr1x, held the same roles at Arine Inc. Lis will become chairman of the board...